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Is there any more grotesque example
of an imbalance between the cost
and benefit of an immune response
than anaphylaxis? On exposure to
even minute amounts of material
containing the offending allergen
(such as peanuts), the unfortunate
subject experiences within minutes a
reaction that can include nausea and
vomiting, hives, difficulty breathing
and rapid circulatory collapse.
Although anaphylaxis,
fortunately, is uncommon, allergic
disorders in general are both very
common and relentlessly increasing
in incidence. In the US alone, 8–10%
of children now suffer from
asthma — a syndrome characterized
by reversible airway narrowing,
airway hyper-reactivity and
inflammation of the airways. The
annual cost of treating asthma in the
US is estimated to be $6 billion.
When one adds in subjects with
other allergic diseases, such as hay
fever (allergic rhinitis) and atopic
dermatitis (also known as eczema),
roughly 20–25% of citizens of the
industrialized nations are affected.
Host defense gone awry
Anaphylaxis does not occur on first
exposure to the allergen but after a
subsequent challenge. In the
intervening interval, the subject has
become sensitized or ‘allergic’ to the
agent. An allergen ordinarily has
little or no intrinsic toxicity (apart
from components of insect or other
venoms); it might be a component of
a food, an antibiotic, or a wasp sting.
An allergen induces an allergic
response because of its ability to
elicit acquired immunological
responses of distinct types.
The term allergy can be used
quite broadly, to include contact
hypersensitivity responses, such as to
poison ivy or detergents. Such
reactions do not develop immediately
in sensitized subjects but hours or a
few days after exposure to the
antigen. These are examples of
‘delayed hypersensitivity reactions’,
in which T lymphocytes (which must
be recruited to sites of antigen
challenge) are actively involved.
In its most narrow usage, the term
allergy refers to immune responses in
which IgE antibodies play an
important part (see Figure 1). People
with such allergies can experience
reactions within minutes of allergen
challenge. Why is this? Most normal
tissues contain mast cells —
hematopoietic cells with the potential
to release an array of stored or newly
synthesized products (collectively
called ‘mediators’) that can induce
inflammation and/or act as
immunoregulators. In sensitized
subjects, these mast cells have
allergen-specific IgE antibodies
already bound to special receptors
(FcεRI) on their surface. A type of
white blood cell, the basophil, also
expresses FcεRI receptors, although
this cell ordinarily circulates in the
blood and must be recruited into the
peripheral tissues. Individuals with
mast cells and basophils already
bearing allergen-specific IgE are thus
immunologically primed to express
acute or ‘immediate hypersensitivity’
responses upon allergen challenge.
The critical event in such reactions is
the binding of groups of two or more
cell-bound IgE antibodies to
individual allergen molecules; this
induces aggregation of the cells’
FcεRI receptors and that, in turn,
activates an exquisitely regulated
process of signal transduction that
culminates in the release of mediators
and cytokines (see Figure 1).
It’s not easy to see how such a
potentially costly immune response
as the allergic reaction could have
evolved. It turns out that
IgE-associated allergic reactions and
delayed hypersensitivity reactions are
examples of two types of immune
response that are directed by two
distinct subtypes of helper T
lymphocyte (Th cells). These
responses also can be mobilized
against pathogens. In subjects with
helminthic parasites, such as
intestinal worms, the immune
responses are dominated by the
actions of one subtype of helper T
cell, Th2 cells. Th2 cells produce
interleukin-4 (IL-4), IL-13 and other
cytokines. These both drive the
production of IgE and other
antibodies, and promote the
development and function of the
effector cells of these responses,
including mast cells, basophils and
eosinophils (another type of
leukocyte that can express FcεRI).
By contrast, in infections with
intracellular pathogens (including
viruses and certain bacteria or
single-cell parasites) and in delayed
hypersensitivity reactions, the
immune responses are regulated
primarily by Th1 cells. Th1 cells
produce a different pattern of
cytokines than Th2 cells, including
interferon-γ, that not only promote
host defense mechanisms against
intracellular pathogens but also can
suppress the activities of Th2 cells
and the effector cells of Th2-driven
responses. Thus, patients with
IgE-associated allergies or helminthic
parasites can be thought of as having
a ‘Th2-biased’ immune system.
Although the selection pressure to
develop robust immune defenses
against parasites was intense until
very recently (in the under-developed
world, it still is), this is no longer the
case in most human populations in
developed countries. Yet we retain
the ability to recognize and mount
defenses against agents that, at least
operationally, are perceived by the
immune system to be derived from
parasites. It’s not yet clear what
governs which agents will function as
allergens, apart from their prevalence
in the environment, water solubility
and ability to access mucosal surfaces.
Although many allergens are enzymes
(parasites produce many enzymes that
are important in their penetration of
or migration through their hosts),
many others are not.
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Powerful mediators on a hair trigger
Different allergic disorders have
distinct clinical features, partly
because exposure to allergen can
induce three types of reaction, which
differ in their kinetics and in their
pathogenesis (see Figure 1). Acute or
immediate reactions, such as
anaphylaxis, or the acute asthmatic
response, can occur in seconds to
minutes, reflecting primarily the
actions of mediators derived from
mast cells and basophils triggered by
aggregation of their FcεRI receptors.
Late phase reactions, which typically
occur 2–6 hours after allergen
challenge, are a recurrence of signs
and symptoms that develop in
concert with the recruitment of
eosinophils, basophils, Th2 cells and
other circulating leukocytes to the
sites of allergen challenge. In cases of
chronic allergic inflammation Th2
cells, eosinophils and other
leukocytes persist at sites of
repetitive allergen challenge; this
phase of the response can go on for
months or years and can be
associated with long-term structural
and functional changes in the
affected organ, such as the airway
remodeling and hyper-reactivity
observed in asthma.
We are far from fully
understanding the induction and
regulation of the IgE response but
several mechanisms have been
uncovered recently that can enhance
the sensitivity or favor the
persistence of allergic disorders.
First, as plasma levels of total IgE
increase, the amounts of FcεRI on
the surface of mast cells and
basophils increase in parallel. This
not only permits the cells to be
activated by lower concentrations of
allergen but also greatly enhances
the effector function of the cells, as
allergen challenge results in the
release of larger amounts of
mediators including those, like IL-4,
that drive IgE production. Second,
IgE can bind to macrophages and
dendritic cells, in part via FcεRI, and
can focus allergen onto these
antigen-presenting cells; this can
favor the further development of
Th2 responses. Finally, in chronic
allergic inflammation, allergen
exposure can induce many cell types
to release an overlapping panel of
pro-inflammatory and
immunoregulatory mediators and
cytokines. Taken together, these
processes might be the reason why
allergic disorders, if not treated
adequately, can persist and become
more severe.
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Figure 1
Steps in the development (sensitization
phase) and expression (effector phase) of
IgE-associated immune responses, such as
those elicited in response to allergens
derived from parasites or from otherwise
innocuous agents. Dotted lines refer to
potential interactions whose biological
importance is not yet clear. Note that
dendritic cells, such as those in the
respiratory mucosa and the Langerhans’ cells
in the skin, can occur within epithelia, placing
these antigen-presenting cells (APCs) in
position to interact with allergens at or near
the epithelial surface. In the effector phase of
IgE-associated responses, the extent to
which mast cells versus Th2 cells contribute
to the development of various features of
late-phase reactions or chronic allergic
inflammation in different settings may vary. It
is not yet clear whether cells of monocytic
lineage (for example, macrophages,
Langerhans’ cells, or other dendritic cells), in
addition to their function as APCs, also can
represent important IgE-dependent sources
of cytokines and other mediators. The APC
function of such cells can be enhanced,
however, by the binding of allergen to IgE
bound to the cells’ surfaces. (Reproduced,
with permission, from Galli SJ, Lantz CS: In
Fundamental Immunology, 4th edn. Edited by
Paul WE. Philadelphia: Lippincott-Raven;
1999:1127-1174.)
bb10c74.qxd  03/01/2000  02:09  Page R94
Candidate genes
Allergic diseases are strongly familial:
if your identical twin has an allergic
disease, your risk is about 70%; the
risk is about 40% for non-identical
twins. Those with a propensity to
develop allergies to multiple
allergens are called ‘atopic’.
Positional cloning and candidate gene
approaches have identified many
genetic regions or genes associated
with asthma or atopy; unsurprisingly,
several of these encode molecules
involved in the sensitization or
effector phases of allergic reactions.
Genetic regions consistently
identified include those containing
the IL-4/IL-9 interleukin cluster,
interferon-γ, the T-cell receptor α/δ
cluster, regions near the major
histocompatibility complex (MHC)
and the β chain of the FcεRI
receptor. Linkage studies have
implicated loci on chromosomes 2q,
5q, 6q, 12q and 13q as consistently
affecting asthma and atopy.
Candidate gene studies show that
the overall influence of the MHC on
allergies consists of many relatively
small effects.
Because atopic diseases involve
many different genes, it is difficult  to
envision a practical gene therapy
approach for these disorders.
Identifying the genes involved is
likely to help, however, in finding
new drug targets or in predicting the
response to different forms of therapy.
For example, a variant within the
5-lipoxygenase gene is of particular
clinical and pharmacogenetic interest,
in that it has been reported to predict
the clinical response of asthmatics to
the anti-leukotriene agent ABT-761.
There is an intriguing effect of
maternal phenotype on the
inheritance of asthma and atopy.
Maternal alleles of the β chain of
FcεRI, the subunit of the receptor
that functions as an amplifier of
FcεRI-dependent signaling and
mediator production, have been
associated with severe atopy and
eczema. Most evidence, however,
indicates that the maternal effect on
atopy reflects the influence of many
different genes, as well as non-genetic
factors such as breast feeding.
Development of allergic responses
Genetic factors alone can not explain
the extraordinary recent increase in
the incidence of allergic disorders.
Accordingly, the search for
contributing environmental factors
has been intense. Initial sensitization
to common airborne allergens often
occurs in very early childhood.
Although this may partly reflect a
genetically determined propensity in
such subjects to maintain the bias
toward a Th2 pattern of
immunological reactivity that
characterizes the fetal state, the
likelihood of developing
sensitization to particular airborne
allergens seems to be highly
dependent on environmental factors.
Many aspects of a western
lifestyle may contribute to the
increased prevalence of allergic
disease, including the improved
heating and humidification of homes
(which favour the proliferation of
house dust mites, a major source of
airborne allergens), a reduced
incidence of common childhood
infections (which may allow a
persistent Th2-bias of the immune
system), and even the increase in the
amount of time many children spend
indoors. In both Europe and Africa, a
rural lifestyle seems to be protective
against atopic disease, as is, in some
populations, having farm animals
near the house or owning a dog. It is
likely, however, that many different
aspects of the clean western lifestyle
contribute to the development of
allergies, rather than a single
dominant environmental factor.
Lifelong management versus cure
Conventional pharmacological
treatment of allergic diseases
focuses on interrupting the chain
of pathogenesis in affected
subjects, including interfering with
mediator production by effector cells,
blocking the actions of mediators on
their cellular targets, improving the
function of affected airway smooth
muscle or blood vessels and using
corticosteroids to suppress chronic
allergic inflammation. Allergen
avoidance remains an important part
of management. 
In certain cases, including insect
venom anaphylaxis and hay fever,
repetitive (and very careful) injection
of tiny but progressively increasing
amounts of the allergen can greatly
reduce or eliminate allergic
reactivity. The underlying basis for
such ‘allergen immunotherapy’
continues to be debated. The
success of this approach in some
subjects, however, offers the promise
that other manipulations of the
immune system might be devised to
treat or eliminate serious allergies, or
even to prevent the development of
these disorders. Some specific
approaches are already being
developed. Yet, for the present at
least, most allergy sufferers face years
of management and treatment rather
than the prospect of a durable cure.
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